Randomized, Controlled Phase II Study of Immunotherapy Versus Standard Chemotherapy as Adjuvant Therapy After Surgery for Colon Cancer With MSI-H or POLE/ POLD1 Mutations
Latest Information Update: 25 Sep 2021
At a glance
- Drugs Tislelizumab (Primary) ; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Colon cancer
- Focus Therapeutic Use
- 23 Jul 2021 New trial record